These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 31150120)

  • 61. Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
    Lee YJ; Lee CG; Cho BC; Kim GE; Choi HJ; Choi EC; Sohn JH; Kim JH
    Head Neck; 2010 Feb; 32(2):235-43. PubMed ID: 19572288
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A comparative study of the treatment outcome of moderately accelerated radiation fractionation (with concurrent chemotherapy in daily dosing) to conventional chemo-radiotherapy in locally advanced head and neck cancers: Supportive in a resource constrained environment.
    Arora C; Sharma N; Kapoor A; Pandya TN
    Indian J Cancer; 2024 Apr; 61(2):262-272. PubMed ID: 38090961
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
    Tao Y; Auperin A; Blanchard P; Alfonsi M; Sun XS; Rives M; Pointreau Y; Castelli J; Graff P; Wong Hee Kam S; Thariat J; Veresezan O; Heymann S; Renard-Oldrini S; Lafond C; Cornely A; Casiraghi O; Boisselier P; Lapeyre M; Biau J; Bourhis J
    Radiother Oncol; 2020 Sep; 150():18-25. PubMed ID: 32417348
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
    Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
    Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
    Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Association of low adherence to weekly cisplatin with outcomes in patients with head and neck squamous cell carcinoma: a retrospective cohort study.
    Virk J; Gill J; Fekrmandi F; Iovoli A; Farrugia M; Al-Afif A; Wooten K; Gupta V; McSpadden R; Kuriakose MA; Markiewicz MR; Hicks WL; Ma SJ; Singh AK
    BMC Cancer; 2024 Jul; 24(1):838. PubMed ID: 39003442
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anti‑epidermal growth factor receptor monoclonal antibody therapy in locally advanced head and neck cancer: A systematic review of phase III clinical trials.
    Nair LM; Ravikumar R; Rafi M; Poulose JV; Jose N; Pisharody K; Thommachan KC
    Med Int (Lond); 2024; 4(4):41. PubMed ID: 38873325
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
    Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
    Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Weekly Cisplatin-Based Concurrent Chemoradiotherapy for Treatment of Locally Advanced Head and Neck Cancer: a Single Institution Study.
    Ghosh S; Rao PB; Kumar PR; Manam S
    Asian Pac J Cancer Prev; 2015; 16(16):7309-13. PubMed ID: 26514529
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
    Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
    Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
    Bourhis J; Burtness B; Licitra LF; Nutting C; Schoenfeld JD; Omar M; Bouisset F; Nauwelaerts H; Urfer Y; Zanna C; Cohen EE
    Future Oncol; 2022 May; 18(14):1669-1678. PubMed ID: 35172587
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial.
    Sharma A; Mohanti BK; Thakar A; Bahadur S; Bhasker S
    Ann Oncol; 2010 Nov; 21(11):2272-2277. PubMed ID: 20427350
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
    Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
    Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer.
    Melotek JM; Cooper BT; Koshy M; Silverman JS; Spiotto MT
    J Otolaryngol Head Neck Surg; 2016 Nov; 45(1):62. PubMed ID: 27881143
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
    Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
    Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
    Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?
    Rades D; Seidl D; Janssen S; Bajrovic A; Hakim SG; Wollenberg B; Schild SE
    Oral Oncol; 2016 Jun; 57():40-5. PubMed ID: 27208843
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
    Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
    Chang CL; Yuan KS; Wu SY
    Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.
    Kataoka T; Kiyota N; Shimada T; Funakoshi Y; Chayahara N; Toyoda M; Fujiwara Y; Nibu K; Komori T; Sasaki R; Mukohara T; Minami H
    Auris Nasus Larynx; 2016 Dec; 43(6):677-84. PubMed ID: 26992271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.